Aptahem

Aptahem Net Debt

The Net Debt of Aptahem (APTA.SL) as of Nov 4, 2026 is -4.13 M SEK. In the previous year, Net Debt was 2.91 M SEK — a change of -242.04% (lower).

Net Debt

-4.13 MSEK

YoY

-242.04%

Last updated:

Net Debt of Aptahem is 2024 -4.13 M SEK. Net Debt of Aptahem was 2023 2.91 M SEK. It decreases by -242.04% lower compared to the previous year.

The Aptahem Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
-24.69 M SEK
Jan 1, 2018
-29.20 M SEK
Jan 1, 2019
-21.88 M SEK
Jan 1, 2020
-28.56 M SEK
Jan 1, 2021
-46.24 M SEK
Jan 1, 2022
-20.23 M SEK
Jan 1, 2023
2.91 M SEK
Jan 1, 2024
-4.13 M SEK
The Aptahem Net Debt history
YEARNet DebtYoY
-4.13 MSEK-242.04%
2.91 MSEK-114.38%
-20.23 MSEK-56.25%
-46.24 MSEK+61.89%
-28.56 MSEK+30.56%
-21.88 MSEK-25.08%
-29.20 MSEK+18.28%
-24.69 MSEK+17.73%
-20.97 MSEK+367.04%
-4.49 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptahem Stock analysis

What does Aptahem do? Aptahem AB is a biotechnology company based in Malmö, Sweden, operating within the healthcare sector. The company focuses on developing drug candidates aimed at treating and preventing diseases caused by blood vessel blockages due to blood clots, including conditions such as deep vein thrombosis, stroke, and heart failure. Aptahem AB went public through an IPO on April 17, 2015, and is listed under the ticker APTA.SL with ISIN SE0022447173. The company's headquarters are located in Malmö, a city in the Skåne region of Sweden. While the source material mentions a founding year of 2014, this detail is not confirmed by the provided facts, so it is omitted. Aptahem AB's website, aptahem.com, serves as the primary online resource for information about the company's activities and developments. The company operates in the biotechnology industry, specializing in therapeutic solutions for cardiovascular and related conditions. As a publicly traded entity, Aptahem AB is subject to the regulatory requirements of the Swedish financial market. The firm's strategic focus lies in addressing unmet medical needs through innovative drug development, targeting conditions that significantly impact patient outcomes and healthcare systems. The company's operations are centered in Malmö, reflecting its commitment to contributing to the biotechnology ecosystem in southern Sweden. Aptahem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptahem stock

Net Debt of Aptahem is -4.13 M SEK in 2024.

Net Debt of Aptahem changed from 2.91 M SEK to -4.13 M SEK, representing a -242.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Aptahem since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Aptahem historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aptahem

All Key Metrics — Aptahem